These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32789657)

  • 1. Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies.
    Kwon SH; Park HS; Na YJ; Park C; Shin JY; Kim HL
    Appl Health Econ Health Policy; 2021 May; 19(3):439-450. PubMed ID: 32789657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 4. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Pricing in South Korea.
    Kwon HY; Godman B
    Appl Health Econ Health Policy; 2017 Aug; 15(4):447-453. PubMed ID: 28138932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
    Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
    BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
    Kwon HY; Hong JM; Godman B; Yang BM
    Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?
    Son KB
    Front Public Health; 2022; 10():934161. PubMed ID: 36187703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of the expiry of the patent on quality and price of medicines at hospital: Study of five anticancer drugs from 2008 to 2015 at the Assistance publique-Hôpitaux de Paris].
    Siorat V; Raybaut C; Poisson N; Paubel P
    Ann Pharm Fr; 2017 Jan; 75(1):59-66. PubMed ID: 27423185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea.
    Kwon HY; Bae S; Choi SE; Park S; Lee EK; Park S; Kim J
    Health Policy; 2019 Apr; 123(4):388-392. PubMed ID: 30503763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is greater generic competition also linked to lower drug prices in South Korea?
    Son KB
    Health Econ Rev; 2020 Sep; 10(1):30. PubMed ID: 32930889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the difference between forecasted and actual drug sales volumes under the price-volume agreement in South Korea.
    Park SY; Han E; Kim J; Lee EK
    Health Policy; 2016 Aug; 120(8):867-74. PubMed ID: 27346072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.